RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Repare Therapeutics Stock

Repare Therapeutics Stocks 2024

Repare Therapeutics Stocks

42.09 M

Ticker

RPTX

ISIN

US7602731025

WKN

A2P7AV

In 2024, Repare Therapeutics had 42.09 M outstanding stocks, a 0% change from the 42.09 M stocks in the previous year.

The Repare Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2028e42.09
2027e42.09
2026e42.09
2025e42.09
2024e42.09
202342.09
202241.9
202137.8
202036.9
201935
201835
201735

Repare Therapeutics shares outstanding

The number of shares was Repare Therapeutics in 2023 — This indicates how many shares 42.093 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Repare Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Repare Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Repare Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Repare Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Repare Therapeutics Aktienanalyse

What does Repare Therapeutics do?

Repare Therapeutics Inc is a biotechnology company specializing in the development of precision medicines for the treatment of cancer. It was founded in 2016 by four leading scientists and is headquartered in Montreal, Canada. The company utilizes an innovative and unique approach called CRISPR-Cas9 to identify and target genetic mutations in cancer cells. The history of Repare Therapeutics Inc stems from a collaboration among renowned cancer researchers. In 2016, the founders, who already had extensive experience in drug development, pooled their resources to create a new generation of cancer therapies. Using the innovative CRISPR-Cas9 system, they were able to specifically identify genetic alterations in cancer cells and significantly reduce tumor burden. Since its inception, the company has formed strong partnerships and successfully raised capital to continue its research and development. Repare Therapeutics has a unique business model focused on developing precision medicine for patients with specific types of cancer. The company combines CRISPR-Cas technology and machine learning to identify genetic mutations in cancer cells and correlate them with an extensive dataset of available clinical studies. This systematic approach allows for faster and more precise identification of suitable target molecules that may serve as potential therapy options for cancer. Repare Therapeutics specializes in quickly and efficiently developing molecules that target these target molecules and advancing them through clinical trials. The company distributes its precision medicines in three different sectors: oncology, therapeutics, and research. The oncology sector specializes in the development of precision medicines for the treatment of cancer. The therapeutics sector offers solutions for the medical care of patients through the development of novel therapies. The research department focuses on developing new precision medicines and advancing innovations in cancer research. Repare Therapeutics offers various products tailored to the needs of cancer patients. The CRISPR-Cas9 technology is being used to advance multiple clinical programs aimed at regulating gene expression in tumor cells and enhancing the effectiveness of cancer therapies. The company's flagship product, RP-3500, is a precision medicine specifically targeted against a gene called KRAS, which plays a crucial role in many types of cancer. The medication has demonstrated strong efficacy in clinical trials and is currently in Phase 1 studies. In summary, Repare Therapeutics Inc is an innovative biotechnology company specializing in the development of precision medicines against cancer. The use of CRISPR-Cas9 technology in combination with machine learning allows for faster identification of suitable target molecules that may serve as potential therapy options for cancer. The company offers various precision medicines that benefit cancer patients. With its numerous research programs and clinical trials, Repare Therapeutics is poised to become a leading player in cancer treatment and research. Repare Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Repare Therapeutics's Shares Outstanding

Repare Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Repare Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Repare Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Repare Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Repare Therapeutics stock

How many stocks are there of Repare Therapeutics?

The current number of stocks of Repare Therapeutics is 42.09 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Repare Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Repare Therapeutics evolved in recent years?

The number of shares of Repare Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Repare Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Repare Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Repare Therapeutics pay?

Over the past 12 months, Repare Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Repare Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Repare Therapeutics?

The current dividend yield of Repare Therapeutics is .

When does Repare Therapeutics pay dividends?

Repare Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Repare Therapeutics?

Repare Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Repare Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Repare Therapeutics located?

Repare Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Repare Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Repare Therapeutics from 10/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/26/2024.

When did Repare Therapeutics pay the last dividend?

The last dividend was paid out on 10/26/2024.

What was the dividend of Repare Therapeutics in the year 2023?

In the year 2023, Repare Therapeutics distributed 0 USD as dividends.

In which currency does Repare Therapeutics pay out the dividend?

The dividends of Repare Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Repare Therapeutics

Our stock analysis for Repare Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repare Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.